Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity
- PMID: 8484693
- PMCID: PMC1005625
- DOI: 10.1136/ard.52.4.272
Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity
Abstract
Objectives: The differential expression of several accessory/activation molecules (CD26, CD29, CD45RA, CD25, MLR4, HLA-DR) on peripheral blood CD4+ and CD8+ T lymphocytes in patients with scleroderma was compared with that in controls and patients with other connective systemic diseases to look for evidence of the involvement of T cells in the disease process of scleroderma.
Methods: The two colour expression of surface molecules by circulating T cells was analysed with a panel of monoclonal antibodies and flow cytometry in 17 patients with scleroderma, 10 patients with systemic lupus erythematosus, and five patients with rheumatoid arthritis, and the results compared with those for 10 normal controls. The two colour T CD4+ phenotype was further compared between patients with active and quiescent disease in these patients with scleroderma. The coexpression of surface molecules by CD4+ T cells was also analysed by three colour flow cytometry in eight patients with scleroderma.
Results: Patients with scleroderma showed increased CD4+CD26+ and CD4+CD25+ percentages and absolute numbers and decreased CD8+CD29+ percentages compared with controls. Moreover, a significant correlation between the higher CD4+CD26+ T cell percentage and absolute cell numbers with disease activity was observed. Most of the CD4+ peripheral blood T cells from patients with scleroderma showed the CD26+CD45RA- phenotype by three colour flow cytometry analysis.
Conclusions: The distinctive pattern of early helper memory T cell activation in these patients with rapidly evolving scleroderma supports the role of a T cell mediated mechanism in the progression of scleroderma.
Similar articles
-
Effect of D-penicillamine on the T cell phenotype in scleroderma. Comparison between treated and untreated patients.Clin Exp Rheumatol. 1993 Mar-Apr;11(2):143-8. Clin Exp Rheumatol. 1993. PMID: 7685256
-
Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs.Clin Immunol Immunopathol. 1994 Feb;70(2):159-65. doi: 10.1006/clin.1994.1024. Clin Immunol Immunopathol. 1994. PMID: 8299231
-
Abnormalities of T lymphocyte subsets in systemic sclerosis demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies.Ann Rheum Dis. 1991 Jun;50(6):354-8. doi: 10.1136/ard.50.6.354. Ann Rheum Dis. 1991. PMID: 1711833 Free PMC article.
-
In situ activation of helper T cells in the lung.Infect Immun. 2001 Aug;69(8):4790-8. doi: 10.1128/IAI.69.8.4790-4798.2001. Infect Immun. 2001. PMID: 11447152 Free PMC article.
-
T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.Clin Rev Allergy Immunol. 2015 Dec;49(3):347-69. doi: 10.1007/s12016-015-8505-8. Clin Rev Allergy Immunol. 2015. PMID: 26445774 Review.
Cited by
-
Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors.J Inflamm Res. 2024 Mar 23;17:1897-1917. doi: 10.2147/JIR.S442106. eCollection 2024. J Inflamm Res. 2024. PMID: 38544813 Free PMC article. Review.
-
Characterisation of the immune response to type I collagen in scleroderma.Arthritis Res Ther. 2006;8(4):R136. doi: 10.1186/ar2025. Arthritis Res Ther. 2006. PMID: 16879746 Free PMC article.
-
Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis.Clin Exp Immunol. 2002 Dec;130(3):548-56. doi: 10.1046/j.1365-2249.2002.02017.x. Clin Exp Immunol. 2002. PMID: 12452848 Free PMC article.
-
Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B.J Clin Immunol. 2004 Jan;24(1):30-6. doi: 10.1023/B:JOCI.0000018060.36183.bb. J Clin Immunol. 2004. PMID: 14997031
-
Natural Killer Cells: Potential Biomarkers and Therapeutic Target in Autoimmune Diseases?Front Immunol. 2021 Feb 19;12:616853. doi: 10.3389/fimmu.2021.616853. eCollection 2021. Front Immunol. 2021. PMID: 33679757 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous